Abstract：
BACKGROUND: Serum tumor markers have not yet been developed for the clinical diagnosis and treatment of sinonasal inverted papilloma (SNIP), one of the most significant sinonasal tumors. Therefore, this study aimed to determine the diagnostic value of serum squamous cell carcinoma antigen (SCCA) and cytokeratin fragment antigen 21-1 (CYFRA 21-1) for SNIP.
METHODS: Clinical data were obtained from 101, 56, and 116 patients with SNIP, sinonasal squamous cell carcinoma (SNSCC), and unilateral chronic rhinosinusitis (CRS), respectively. Preoperative serum SCCA and CYFRA 21-1 levels were compared, and logistic regression analyses were performed to screen serum tumor markers, which may be used to diagnose SNIP. Diagnostic cut-off values were determined using receiver operating characteristic (ROC) curves, and their diagnostic power was verified.
RESULTS: Serum SCCA and CYFRA 21-1 differentiated SNIP from CRS with the cut-off values of 1.97 ng/mL and 2.64 ng/mL and the areas under the ROC curves (AUC) of 0.895 and 0.766, respectively, and the AUC of the combination of the two markers was 0.909. CYFRA 21-1 differentiated SNIP with malignant transformation from that without malignant transformation with a cut-off value of 3.51 ng/mL and an AUC of 0.938. CYFRA 21-1 distinguished SNIP with malignant transformation from SNSCC with a cut-off value of 3.55 ng/mL and an AUC of 0.767.
CONCLUSIONS: This study provides novel potential diagnostic tools for SNIP by demonstrating the use of serum SCCA and CYFRA 21-1 in the diagnosis of SNIP.
METHODS: Clinical data were obtained from 101, 56, and 116 patients with SNIP, sinonasal squamous cell carcinoma (SNSCC), and unilateral chronic rhinosinusitis (CRS), respectively. Preoperative serum SCCA and CYFRA 21-1 levels were compared, and logistic regression analyses were performed to screen serum tumor markers, which may be used to diagnose SNIP. Diagnostic cut-off values were determined using receiver operating characteristic (ROC) curves, and their diagnostic power was verified.
RESULTS: Serum SCCA and CYFRA 21-1 differentiated SNIP from CRS with the cut-off values of 1.97 ng/mL and 2.64 ng/mL and the areas under the ROC curves (AUC) of 0.895 and 0.766, respectively, and the AUC of the combination of the two markers was 0.909. CYFRA 21-1 differentiated SNIP with malignant transformation from that without malignant transformation with a cut-off value of 3.51 ng/mL and an AUC of 0.938. CYFRA 21-1 distinguished SNIP with malignant transformation from SNSCC with a cut-off value of 3.55 ng/mL and an AUC of 0.767.
CONCLUSIONS: This study provides novel potential diagnostic tools for SNIP by demonstrating the use of serum SCCA and CYFRA 21-1 in the diagnosis of SNIP.
摘要：
背景：尚未开发用于临床诊断和治疗鼻窦内翻性乳头状瘤（SNIP）的血清肿瘤标志物，最重要的鼻窦肿瘤之一。因此,本研究旨在确定血清鳞状细胞癌抗原（SCCA）和细胞角蛋白片段抗原21-1（CYFRA21-1）对SNIP的诊断价值。
方法：获得了101、56和116例SNIP患者的临床数据，鼻窦鳞状细胞癌（SNSCC），和单侧慢性鼻-鼻窦炎（CRS），分别。术前血清SCCA和CYFRA21-1水平比较,和logistic回归分析用于筛选血清肿瘤标志物，可用于诊断SNIP。使用受试者工作特征（ROC）曲线确定诊断临界值，他们的诊断能力得到了验证。
结果：血清SCCA和CYFRA21-1区分SNIP和CRS的临界值分别为1.97ng/mL和2.64ng/mL，ROC曲线下面积（AUC）分别为0.895和0.766，两种标志物组合的AUC为0.909。CYFRA21-1从没有恶性转化的SNIP中分化出具有恶性转化的SNIP，其临界值为3.51ng/mL，AUC为0.938。CYFRA21-1将具有恶性转化的SNIP与SNSCC区分开，其临界值为3.55ng/mL，AUC为0.767。
结论：本研究通过证明血清SCCA和CYFRA21-1在SNIP诊断中的应用，为SNIP提供了新的潜在诊断工具。
方法：获得了101、56和116例SNIP患者的临床数据，鼻窦鳞状细胞癌（SNSCC），和单侧慢性鼻-鼻窦炎（CRS），分别。术前血清SCCA和CYFRA21-1水平比较,和logistic回归分析用于筛选血清肿瘤标志物，可用于诊断SNIP。使用受试者工作特征（ROC）曲线确定诊断临界值，他们的诊断能力得到了验证。
结果：血清SCCA和CYFRA21-1区分SNIP和CRS的临界值分别为1.97ng/mL和2.64ng/mL，ROC曲线下面积（AUC）分别为0.895和0.766，两种标志物组合的AUC为0.909。CYFRA21-1从没有恶性转化的SNIP中分化出具有恶性转化的SNIP，其临界值为3.51ng/mL，AUC为0.938。CYFRA21-1将具有恶性转化的SNIP与SNSCC区分开，其临界值为3.55ng/mL，AUC为0.767。
结论：本研究通过证明血清SCCA和CYFRA21-1在SNIP诊断中的应用，为SNIP提供了新的潜在诊断工具。
